What is the price-to-earnings ratio of Atara Biotherapeutics?
The price-earnings ratio of Atara Biotherapeutics is currently 0.54.
Atara Biotherapeutics P/S 2024
Atara Biotherapeutics P/S
0.54
Ticker
ATRA
ISIN
US0465131078
WKN
A1166A
As of Jul 2, 2024, Atara Biotherapeutics's P/S ratio stood at 0.54, a -97.09% change from the 18.53 P/S ratio recorded in the previous year.
The Atara Biotherapeutics P/S history
Atara Biotherapeutics Aktienanalyse
What does Atara Biotherapeutics do?
Atara Biotherapeutics Inc. is a biotechnology company founded in 2012 by Isaac Ciechanover. The company is headquartered in South San Francisco, California, and its goal is to develop innovative immunotherapies for the treatment of severe diseases. Atara Biotherapeutics is listed on the NASDAQ stock exchange and has a market capitalization of approximately $1.8 billion. The company's business model focuses on the development of new therapies based on T-cells, the body's own defense cells. T-cells play an important role in fighting diseases like cancer and viral infections. Atara Biotherapeutics is working on leading-edge immunotherapy based on gene-editing to selectively manipulate T-cells to fight certain hard-to-treat diseases. The company has several divisions, including therapy development, clinical research, drug manufacturing, and commercial distribution channels. Its primary focus is on three therapy areas: oncology, virus infections, and autoimmune diseases. Atara Biotherapeutics has partnerships and licensing agreements with leading players in the industry, such as Allergen, Memorial Sloan Kettering Cancer Center, and QIMR Berghofer Medical Research Institute. It has several products in its portfolio, including ATA188 for the treatment of progressive multifocal leukoencephalopathy (PML) and ATA-2271 for mesothelioma. The company also has a pipeline of promising product candidates in various stages of clinical development for cancer, virus infections, and autoimmune diseases. Overall, Atara Biotherapeutics is a leading biotechnology company focused on developing innovative therapies to combat severe diseases. It is well-positioned in the field of immunotherapy with its strong research pipeline, partnerships, licenses, and experienced leadership team. Atara Biotherapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Atara Biotherapeutics's P/S Ratio
Atara Biotherapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Atara Biotherapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Atara Biotherapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Atara Biotherapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Atara Biotherapeutics Stock
How has the price-earnings ratio of Atara Biotherapeutics changed compared to last year?
The price-to-earnings ratio of Atara Biotherapeutics has increased by -97.09% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Atara Biotherapeutics high compared to other companies?
Yes, the price-to-earnings ratio of Atara Biotherapeutics is high compared to other companies.
How does an increase in the price-earnings ratio of Atara Biotherapeutics affect the company?
An increase in the price-earnings ratio of Atara Biotherapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Atara Biotherapeutics affect the company?
A decrease in the price-earnings ratio of Atara Biotherapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Atara Biotherapeutics?
Some factors that influence the price-earnings ratio of Atara Biotherapeutics are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Atara Biotherapeutics pay?
Over the past 12 months, Atara Biotherapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Atara Biotherapeutics is expected to pay a dividend of 0 USD.
What is the dividend yield of Atara Biotherapeutics?
The current dividend yield of Atara Biotherapeutics is .
When does Atara Biotherapeutics pay dividends?
Atara Biotherapeutics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Atara Biotherapeutics?
Atara Biotherapeutics paid dividends every year for the past 0 years.
What is the dividend of Atara Biotherapeutics?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Atara Biotherapeutics located?
Atara Biotherapeutics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Atara Biotherapeutics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Atara Biotherapeutics from 7/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/2/2024.
When did Atara Biotherapeutics pay the last dividend?
The last dividend was paid out on 7/2/2024.
What was the dividend of Atara Biotherapeutics in the year 2023?
In the year 2023, Atara Biotherapeutics distributed 0 USD as dividends.
In which currency does Atara Biotherapeutics pay out the dividend?
The dividends of Atara Biotherapeutics are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Atara Biotherapeutics stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Atara Biotherapeutics
Our stock analysis for Atara Biotherapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Atara Biotherapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Atara Biotherapeutics Revenue
- Atara Biotherapeutics Net Income
- Atara Biotherapeutics P/E
- Atara Biotherapeutics P/S
- Atara Biotherapeutics EBIT
- Atara Biotherapeutics Dividend
- Atara Biotherapeutics Stocks
- Atara Biotherapeutics Market capitalization
- Atara Biotherapeutics Debt
- Atara Biotherapeutics Liabilities
- Atara Biotherapeutics Equity
- Atara Biotherapeutics AAQS
- Atara Biotherapeutics Employees
- Atara Biotherapeutics ROE
- Atara Biotherapeutics ROA
- Atara Biotherapeutics ROCE
